Evidence map›Paper›PMID 41607427›Full record

ArticleResearch in pharmaceutical sciences2026

The effect of estradiol and selective estrogen receptor modulators on lipid profile in the ovariectomized rat model.

Hossein Babaahmadi-Rezaei, Saleh Aiiashi, Alireza Kheirollah, Hamid Yaghooti

Abstract read
In one paragraph

Article in Research in pharmaceutical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hossein Babaahmadi-RezaeiHyperlipidemia Research Center, Department of Clinical Biochemistry, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, I.R. Iran.
Saleh AiiashiHyperlipidemia Research Center, Department of Clinical Biochemistry, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, I.R. Iran.
Alireza KheirollahCellular and Molecular Research Center, Department of Clinical Biochemistry, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, I.R. Iran.
Hamid YaghootiDepartment of Clinical Biochemistry, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, I.R. Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and purpose: Menopause can increase the risk of cardiovascular diseases, diabetes mellitus, and metabolic syndrome, principally due to estrogen deficiency. In the current experiment, protective effects of selective estrogen receptor modulators (SERMs) and estradiol (E2), alone and combined, were evaluated in a rat model of menopause. Experimental approach: Forty-eight female Wistar rats underwent ovariectomy to induce a menopause model. Then, the animals were subjected to receive SERMs including tamoxifen (TAM), raloxifene (RAL), and bazedoxifene (BZA) and E2. Finally, serum and liver tissue samples were collected post-treatment for experimental analysis. Findings/Results: The induction of menopause by ovariectomy reduced the body weight of animals and altered their food intake. TAM, RAL, ethinyl E2 (EE2), and BZA/conjugated estrogens (BZA/CE) improved the ovariectomy-induced elevation of total cholesterol and low-density lipoprotein (LDL) cholesterol significantly. In this regard, the lowering effects of SERMs were significantly greater than EE2. The increased levels of triglycerides were also alleviated by RAL, EE2, and BZA/CE but not TAM. Moreover, the combination of SERMs, especially BZA/CE therapy, had significantly increasing effects on high-density lipoprotein (HDL) cholesterol levels, in a more effective manner than E2 therapy alone. Low-density lipoprotein receptor gene and protein expression levels were also significantly increased by SERMs. The HDL2 subfraction was found to be significantly enhanced in TAM, RAL, and BZA/CE therapy. Conclusion and implications: The therapy with SERMs, alone or in combination with E2, may be efficiently utilized instead of E2 replacement therapy in post-menopausal conditions.

Indexed as

Cardiovascular diseasesEstradiolEstrogen replacement therapyLipidsMenopause

Identifiers

PMID41607427
PMCPMC12840871

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.